To include your compound in the COVID-19 Resource Center, submit it here.

Arena preclinical data

Arena and partner Eisai Co. Ltd. (Tokyo:4523; Osaka:4523, Tokyo, Japan) reported data from a re-adjudication of female rat mammary tumor diagnoses for lorcaserin in a 2-year carcinogenicity study showing that the percentage of malignant tumors was lower for all dose groups

Read the full 412 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers